[1] MATULONIS U A,SOOD A K,FALLOWFIELD L,et al.Ovarian cancer[J].Nat Rev Dis Primers,2016,2:16061.
[2] MOORE K N,OZA A M,COLOMBO N,et al.Phase Ⅲ,randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer:primary analysis of FORWARD Ⅰ[J].Ann Oncol,2021,32(6):757-765.
[3] 赵灵.化疗对上皮性卵巢癌免疫逃逸相关分子CD47和PD-L1表达的影响[D].北京:北京协和医学院,2018.
[4] SHAO F,LIU J,DUAN Y,et al.Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer:a meta-analysis of nine randomized controlled trials[J].Biosci Rep,2020,40(3):BSR20192226.
[5] GOODELL V,SALAZAR L G,URBAN N,et al.Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer[J].J Clin Oncol,2006,24:762-768.
[6] SATO E,OLSON S H,AHN J,et al.Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer[J].Proc Natl Acad Sci U S A,2005,102(51):18538-18543.
[7] ZSIROS E,TANYI J,BALINT K,et al.Immunotherapy for ovarian cancer:recent advances and perspectives[J].Curr Opin Oncol,2014,26(5):492-500.
[8] KAWANO K,TSUDA N,MATSUEDA S,et al.Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients[J].Immunopharmacol Immunotoxicol,2014,36:224-236.
[9] SPINOSA J P,KANDUC D.Ovarian cancer:designing effective vaccines and specific diagnostic tools[J].Immunotherapy,2014,6:35-41.
[10] ALESSANDRA B,MARCO F,ALEXIA B,et al.A robust immune system conditions the responseto abagovomab(anti-idiotypic monoclonal antibody mimicking the ca125 protein) vaccination in ovarian cancer patients[J].Immunol Lett,2017,191:35-39.
[11] CHENG H,YE X,CHANG X,et al.Construction,expression,and function of 6B11ScFv-mIL-12,a fusion protein that attacks human ovarian carcinoma[J].Med Oncol,2015,32(4):130.
[12] SENOVILLA L,VACCHELLI E,GARCIA P,et al.Trial watch:DNA vaccines for cancer therapy[J].Oncoimmunology,2013,2(4):e23803.
[13] DOWD K A,KO S Y,MORABITO K M,et al.Rapid development of a DNA vaccine for Zika virus[J].Science,2016,354:237-240.
[14] BARRETT ALAN D T.Zika vaccine candidates progress through nonclinical development and enter clinical trials[J].NPJ Vaccines,2016,1:16023.
[15] PERALES P A,WOJTAK K,DUPERRET E K,et al.Engineered DNA vaccination against follicle-stimulating hormone receptor delays ovarian cance progression in animal models[J].Mol Ther,2019,27:314-25.
[16] GABAI-VLADIMIR L,SHIFRIN-VICTOR I.Feasibility analysis of p62(SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy[J].Int Rev Immunol,2014,33:375-82.
[17] DMITRY M,PONOMARENKO I D K,YULIA A,et al.Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in human trial in patients with advanced solid tumors[J].Oncotarget,2017,8(32):53730-53739.
[18] LIZOTTE P H,WEN A M,SHEEN M R,et al.In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer[J].Nat Nanotechnol,2016,11(3):295-303.
[19] CZAPAR A E,TIU B D B,VELIZ F A,et al.Slow-release formulation of cowpea mosaic virus for in situ vaccine delivery to treat ovarian cancer[J].Adv Sci(Weinh),2018,5:1700991.
[20] WANG C,STEINMETZ-NICOLE F.CD47 blockade and cowpea mosaic virus nanoparticle in situ vaccination triggers phagocytosis and tumor killing[J].Adv Healthc Mater,2019,8:e1801288.
[21] TSCHOFEN M,KNOPP D,HOOD E,et al.Plant molecular farming:much more than medicines[J].Annu Rev Anal Chem(Palo Alto Calif),2016,9(1):271-294.
[22] KANERVA A,NOKISALMI P,DIACONU I,et al.Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus[J].Clin Cancer Res,2013,19:2734-2744.
[23] WOLLER N,GVRLEVIK E,FLEISCHMANN-MUNDT B,et al.Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses[J].Mol Ther,2015,23:1630-1640.
[24] SANTOS J M,HEINIÖ C,CERVERA C V,et al.Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity[J].J Immunother Cancer,2020,8:e000188.
[25] WU D,WANG J,CAI Y L,et al.Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine[J].J Ovarian Res,2015,8:68.
[26] HELLSTRÖM I,GOODMAN G,PULLMAN J,et al.Overexpression of HER-2 in ovarian carcinomas[J].Cancer Res,2001,61(6):2420-2423.
[27] BORELLA F,GHISONI E,GIANNONE G,et al.Immune checkpoint inhibitors in epithelial ovarian cancer:an overview on efficacy and future perspectives[J].Diagnostics(Basel),2020,10(3):146-163.
[28] CHU C S,Boyer J,Schullery D S,et al.Phase Ⅰ/Ⅱ randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission[J]. Cancer Immunology Immunotherapy, 2012, 61(5):629-641.
[29] SCARANTI M,COJOCARU E,BANERJEE S,et al.Exploiting the folate receptor α in oncology[J].Nat Rev Clin Oncol,2020,17(6):349-359.
[30] BRAND C,SADIQUE A,HOUGHTON J L,et al.Leveraging PET to image folate receptor alpha therapy of an antibody-drug conjugate[J].EJNMMI Res,2018,8(1):87-97.
[31] HERNANDO J J,PARK T W,FISCHER H P,et al.Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-α for relapsed metastatic ovarian cancer[J].Lancet Oncol,2007,8:451-454.
[32] CAO Y,BLOHM D,GHADIMI B M,et al.Mucins(MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumor-associated aberrations in glycosylation[J].J Histochem Cytochem,1997,45:1547-1557.
[33] GRAY H J,BENIGNO B,BEREK J,et al.Progression-free and overall survival in ovarian cancer patients treated with CVac,a mucin 1 dendritic cell therapy in a randomized phase 2 trial[J].J Immunother Cancer,2016,4:34.
[34] CHENG W F,HUANG C Y,CHANG M C,et al.High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma[J].Br J Cancer,2009,100:1144-1153.
[35] 梁振,董郊,李凤杰,等.FOLR1与MSLN蛋白在上皮性卵巢癌组织中的表达及临床意义[J].第三军医大学学报,2020,42(2):133-140.
[36] 王东晖.间皮素在卵巢上皮癌中的诊断价值及负载间皮素的DC疫苗抗卵巢癌细胞效应的研究[D].石家庄:河北医科大学,2015.
[37] FACCIPONTE J G,WANG X Y,MACDONALD I J,et al.Heat shock proteins HSP70 and GP96:structural insights[J].Cancer Immunol Immun,2006,55(3):339-346.
[38] ZHENG H G,LIU L L,ZHANG H,et al.Correction:Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses[J].PLoS One,2019,14:e0218362.
[39] 杨淑莉,金月梅,付莉,等.负载gp96多肽复合物的树突状细胞抗耐药卵巢癌细胞株作用的实验研究[J].中国妇幼保健,2008,33:4759-4762.
[40] MCGRANAHAN N,FURNESS A J S,ROSENTHAL R,et al.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J].Science,2016,351:1463-1469.
[41] MAOZ A,RENNERT G,GRUBER S B.T-cell transfer therapy targeting mutant KRAS[J].N Engl J Med,2017,376:e11.
[42] VAN A E M,MIAO D,SCHILLING B,et al.Genomic correlates of response to CTLA-4 blockade in metastatic melanoma[J].Science,2015,350:207-211.
[43] YADAV M,JHUNJHUNWALA S,PHUNG Q T,et al.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing[J].Nature,2014,515:572-576.
[44] GUBIN M M,ZHANG X L,SCHUSTER H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515:577-581.
[45] OPHIR E,BOBISSE S,COUKOS G,et al.Personalized approaches to active immunotherapy in cancer[J].Biochem Biophys Acta,2016,1865(1):72-82.
[46] SARIVALASIS A,BOUDOUSQUIE C,BALINT K,et al.A Phase Ⅰ/Ⅱ trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides(PEP-DC) or with tumor lysate(OC-DC) in patients with advanced high-grade ovarian serous carcinoma[J]. Transl Med,2019,17:391-401.
[47] TANYI J L,BOBISSE S,OPHIR E,et al.Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer[J].Sci Transl Med,2018,10(436):eaao5931.
[48] CHIANG C L,KANDALAFT L E,TANYI J,et al.A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity:from bench to bedside[J].Clin Cancer Res,2013,19(17):4801-4815.
[49] MARTIN S D,BROWN S D,WICK D A,et al.Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines[J].PLoS ONE,2016,11(5):e0155189.
[50] ODUNSI K,QIAN F,MATSUZAKI J,et al.Vaccination with an NY-ESO-1 peptide of HLA class Ⅰ/Ⅱ specifcities induces integrated humoral and T cell responses in ovarian cancer[J].Proc Natl Acad Sci U S A,2007,104(31):12837-12842.
[51] OTT P A,HU Z,KESKIN D B,et al.An immunogenic personal neoantigen vaccine for patients with melanoma[J].Nature,2017,547:217-221.
[52] OTT P A,GOVINDAN R,NAING A,et al.A personal neoantigen vaccine,NEO-PV-01,with anti-PD1 induces broadde novo anti-tumor immunity in patients with metastatic melanoma,NSCLC and bladder cancer[J].Ann Oncol,2018,29:400-441.
[53] SAHIN U,DERHOVANESSIAN E,MILLER M,et al.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J].Nature,2017,547(7662):222-226. |
